These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

496 related items for PubMed ID: 28774796

  • 1. Synergistic anti-tumor effect of 17AAG with the PI3K/mTOR inhibitor NVP-BEZ235 on human melanoma.
    Calero R, Morchon E, Martinez-Argudo I, Serrano R.
    Cancer Lett; 2017 Oct 10; 406():1-11. PubMed ID: 28774796
    [Abstract] [Full Text] [Related]

  • 2. Dual blockade of PI3K/AKT/mTOR (NVP-BEZ235) and Ras/Raf/MEK (AZD6244) pathways synergistically inhibit growth of primary endometrioid endometrial carcinoma cultures, whereas NVP-BEZ235 reduces tumor growth in the corresponding xenograft models.
    Schrauwen S, Depreeuw J, Coenegrachts L, Hermans E, Lambrechts D, Amant F.
    Gynecol Oncol; 2015 Jul 10; 138(1):165-73. PubMed ID: 25933683
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Synergistic targeted inhibition of MEK and dual PI3K/mTOR diminishes viability and inhibits tumor growth of canine melanoma underscoring its utility as a preclinical model for human mucosal melanoma.
    Wei BR, Michael HT, Halsey CH, Peer CJ, Adhikari A, Dwyer JE, Hoover SB, El Meskini R, Kozlov S, Weaver Ohler Z, Figg WD, Merlino G, Simpson RM.
    Pigment Cell Melanoma Res; 2016 Nov 10; 29(6):643-655. PubMed ID: 27463366
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. NVP-BEZ235, a novel dual PI3K-mTOR inhibitor displays anti-glioma activity and reduces chemoresistance to temozolomide in human glioma cells.
    Yu Z, Xie G, Zhou G, Cheng Y, Zhang G, Yao G, Chen Y, Li Y, Zhao G.
    Cancer Lett; 2015 Oct 10; 367(1):58-68. PubMed ID: 26188279
    [Abstract] [Full Text] [Related]

  • 8. Efficacy of the dual PI3K and mTOR inhibitor NVP-BEZ235 in combination with imatinib mesylate against chronic myelogenous leukemia cell lines.
    Xin P, Li C, Zheng Y, Peng Q, Xiao H, Huang Y, Zhu X.
    Drug Des Devel Ther; 2017 Oct 10; 11():1115-1126. PubMed ID: 28435223
    [Abstract] [Full Text] [Related]

  • 9. Simultaneous perturbation of the MAPK and the PI3K/mTOR pathways does not lead to increased radiosensitization.
    Kuger S, Flentje M, Djuzenova CS.
    Radiat Oncol; 2015 Oct 24; 10():214. PubMed ID: 26498922
    [Abstract] [Full Text] [Related]

  • 10. Upstream and Downstream Co-inhibition of Mitogen-Activated Protein Kinase and PI3K/Akt/mTOR Pathways in Pancreatic Ductal Adenocarcinoma.
    Wong MH, Xue A, Baxter RC, Pavlakis N, Smith RC.
    Neoplasia; 2016 Jul 24; 18(7):425-35. PubMed ID: 27435925
    [Abstract] [Full Text] [Related]

  • 11. Modulation of Glucocorticoid Resistance in Pediatric T-cell Acute Lymphoblastic Leukemia by Increasing BIM Expression with the PI3K/mTOR Inhibitor BEZ235.
    Hall CP, Reynolds CP, Kang MH.
    Clin Cancer Res; 2016 Feb 01; 22(3):621-32. PubMed ID: 26080839
    [Abstract] [Full Text] [Related]

  • 12. Cell cycle-dependent activity of the novel dual PI3K-MTORC1/2 inhibitor NVP-BGT226 in acute leukemia.
    Kampa-Schittenhelm KM, Heinrich MC, Akmut F, Rasp KH, Illing B, Döhner H, Döhner K, Schittenhelm MM.
    Mol Cancer; 2013 May 24; 12():46. PubMed ID: 23705826
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Dual inhibition of the PI3K/AKT/mTOR pathway suppresses the growth of leiomyosarcomas but leads to ERK activation through mTORC2: biological and clinical implications.
    Fourneaux B, Chaire V, Lucchesi C, Karanian M, Pineau R, Laroche-Clary A, Italiano A.
    Oncotarget; 2017 Jan 31; 8(5):7878-7890. PubMed ID: 28002802
    [Abstract] [Full Text] [Related]

  • 15. Dual PI3K/mTOR inhibitor BEZ235 as a promising therapeutic strategy against paclitaxel-resistant gastric cancer via targeting PI3K/Akt/mTOR pathway.
    Chen D, Lin X, Zhang C, Liu Z, Chen Z, Li Z, Wang J, Li B, Hu Y, Dong B, Shen L, Ji J, Gao J, Zhang X.
    Cell Death Dis; 2018 Jan 26; 9(2):123. PubMed ID: 29374144
    [Abstract] [Full Text] [Related]

  • 16. mTOR, p70S6K, AKT, and ERK1/2 levels predict sensitivity to mTOR and PI3K/mTOR inhibitors in human bronchial carcinoids.
    Gagliano T, Bellio M, Gentilin E, Molè D, Tagliati F, Schiavon M, Cavallesco NG, Andriolo LG, Ambrosio MR, Rea F, Degli Uberti E, Zatelli MC.
    Endocr Relat Cancer; 2013 Aug 26; 20(4):463-75. PubMed ID: 23653462
    [Abstract] [Full Text] [Related]

  • 17. The dual PI3K and mTOR inhibitor NVP-BEZ235 exhibits anti-proliferative activity and overcomes bortezomib resistance in mantle cell lymphoma cells.
    Kim A, Park S, Lee JE, Jang WS, Lee SJ, Kang HJ, Lee SS.
    Leuk Res; 2012 Jul 26; 36(7):912-20. PubMed ID: 22560334
    [Abstract] [Full Text] [Related]

  • 18. Multipoint targeting of the PI3K/mTOR pathway in mesothelioma.
    Zhou S, Liu L, Li H, Eilers G, Kuang Y, Shi S, Yan Z, Li X, Corson JM, Meng F, Zhou H, Sheng Q, Fletcher JA, Ou WB.
    Br J Cancer; 2014 May 13; 110(10):2479-88. PubMed ID: 24762959
    [Abstract] [Full Text] [Related]

  • 19. Primary cross-resistance to BRAFV600E-, MEK1/2- and PI3K/mTOR-specific inhibitors in BRAF-mutant melanoma cells counteracted by dual pathway blockade.
    Penna I, Molla A, Grazia G, Cleris L, Nicolini G, Perrone F, Picciani B, Del Vecchio M, de Braud F, Mortarini R, Anichini A.
    Oncotarget; 2016 Jan 26; 7(4):3947-65. PubMed ID: 26678033
    [Abstract] [Full Text] [Related]

  • 20. Inhibition of PI3K/Akt/mTOR overcomes cisplatin resistance in the triple negative breast cancer cell line HCC38.
    Gohr K, Hamacher A, Engelke LH, Kassack MU.
    BMC Cancer; 2017 Nov 03; 17(1):711. PubMed ID: 29100507
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 25.